Quick Answer
Galera Therapeutics, Inc. reported R&D Expense of $349.0 thousand for fiscal year 2025.
Galera Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $349.0K | -88.9% |
| 2024 | $3.15M | -86.9% |
| 2023 | $24.11M | -22.2% |
| 2022 | $31.01M | -40.8% |
| 2021 | $52.42M | -4.4% |
| 2020 | $54.84M | +29.6% |
| 2019 | $42.33M | +126.8% |
| 2018 | $18.66M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $130.0K | -57.4% | +54.8% |
| June 30, 2025 | $84.0K | -94.1% | -9.7% |
| March 31, 2025 | $93.0K | -93.8% | -69.5% |
| September 30, 2024 | $305.0K | -95.0% | -78.7% |
| June 30, 2024 | $1.43M | -81.1% | -3.9% |
| March 31, 2024 | $1.49M | -79.5% | -75.6% |
| September 30, 2023 | $6.09M | -24.8% | -19.4% |
| June 30, 2023 | $7.56M | +13.9% | +4.0% |
- Galera Therapeutics, Inc. showed a decrease of -88.9% in R&D Expense compared to the prior fiscal year.
- Over the 2018–2025 period, Galera Therapeutics, Inc.’s r&d expense has declined by 98.1% (from $18.66 million to $349.0 thousand).
- The most recent figure is from Galera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: